Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mehdi Hamadani

Showing results (161-170 of 460) with videos related to

Pageof 46
Sort By:
Transplantation and Cellular Therapy|June 7, 2022
ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Diffuse Large B-cell Lymphoma after Failure of Chimeric Antigen Receptor T Cell Therapy (CAR-T) TherapyNausheen Ahmed, Ambuj Kumar, Mohamed A Kharfan-Dabaja, et al.
Transplantation and Cellular Therapy|September 21, 2020
Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic TransplantationNarendranath Epperla, Kwang W Ahn, Manoj Khanal, et al.
Blood Advances|September 6, 2019
HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysisMohamad A Meybodi, Wenhao Cao, Leo Luznik, et al.
American Journal of Hematology|September 7, 2022
Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-cellsJoanna C Zurko, Timothy S Fenske, Bryon D Johnson, et al.
Blood Cancer Journal|July 31, 2019
Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myelomaBinod Dhakal, Anita D'Souza, Mehdi Hamadani, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 1, 2017
Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell TransplantationJonathan T Kapke, Narendranath Epperla, Namrata Shah, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 13, 2020
Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for MyelomaKathleen Monahan, Ariel Kleman, Bicky Thapa, et al.
Haematologica|August 30, 2023
Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT studyLeo I Gordon, Fei Fei Liu, Julia Braverman, et al.
JAMA Oncology|January 6, 2018
Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysisBinod Dhakal, Aniko Szabo, Saurabh Chhabra, et al.
Leukemia & Lymphoma|December 30, 2009
Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myelomaDon M Benson, Kathryn Panzner, Mehdi Hamadani, et al.
Pageof 46

Showing results (161-170 of 460) with videos related to

Sort By:
Pageof 46
Transplantation and Cellular Therapy|June 7, 2022
ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Diffuse Large B-cell Lymphoma after Failure of Chimeric Antigen Receptor T Cell Therapy (CAR-T) TherapyNausheen Ahmed, Ambuj Kumar, Mohamed A Kharfan-Dabaja, et al.
Transplantation and Cellular Therapy|September 21, 2020
Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic TransplantationNarendranath Epperla, Kwang W Ahn, Manoj Khanal, et al.
Blood Advances|September 6, 2019
HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysisMohamad A Meybodi, Wenhao Cao, Leo Luznik, et al.
American Journal of Hematology|September 7, 2022
Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-cellsJoanna C Zurko, Timothy S Fenske, Bryon D Johnson, et al.
Blood Cancer Journal|July 31, 2019
Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myelomaBinod Dhakal, Anita D'Souza, Mehdi Hamadani, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 1, 2017
Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell TransplantationJonathan T Kapke, Narendranath Epperla, Namrata Shah, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 13, 2020
Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for MyelomaKathleen Monahan, Ariel Kleman, Bicky Thapa, et al.
Haematologica|August 30, 2023
Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT studyLeo I Gordon, Fei Fei Liu, Julia Braverman, et al.
JAMA Oncology|January 6, 2018
Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysisBinod Dhakal, Aniko Szabo, Saurabh Chhabra, et al.
Leukemia & Lymphoma|December 30, 2009
Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myelomaDon M Benson, Kathryn Panzner, Mehdi Hamadani, et al.
Pageof 46